Common Variable Immunodeficiency

Complex MONDO:0015517 Primary Immunodeficiency Antibody Deficiency Disorder

Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency, characterized by defective B cell differentiation, hypogammaglobulinemia, and failure of antibody production. Patients present with recurrent bacterial infections, particularly of the respiratory and gastrointestinal tracts, and have increased susceptibility to autoimmune manifestations, granulomatous disease, and lymphoproliferative disorders. CVID is best understood as an umbrella diagnosis with heterogeneous genetic and immunologic etiologies spanning monogenic, digenic, and polygenic models.

Ask OpenScientist

Ask a research question about Common Variable Immunodeficiency. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

⚙

Pathophysiology

Defective B Cell Differentiation and Class-Switch Recombination

The hallmark of CVID is a failure of B cells to differentiate into immunoglobulin-secreting plasma cells. Defective class-switch recombination leads to impaired production of IgG, IgA, and often IgM. Most patients show reduced switched memory B cells (CD27+IgD-IgM-). Defects in B cell receptor signaling, BAFF/APRIL axis, and NF-kB signaling all converge on impaired germinal center output.

B cell link Plasma cell link

Immunoglobulin Production link Isotype Switching link B Cell Activation link

Show evidence (2 references)

DOI:10.3390/jcm13061717 SUPPORT Human Clinical

"The pathogenesis of CVID involves complex immunological dysregulation, including defects in B cell development, antibody class switching, and plasma cell differentiation. These abnormalities contribute to an impaired humoral immune response against viral agents, predisposing individuals with..."

This 2024 review confirms that CVID pathogenesis centers on defective B cell development, class switching, and plasma cell differentiation.

PMID:16007086 SUPPORT Human Clinical

"B cells from individuals with TACI mutations expressed TACI but did not produce IgG and IgA in response to the TACI ligand APRIL, probably reflecting impaired isotype switching."

Demonstrates that TACI mutations in CVID patients lead to impaired isotype switching, a key mechanism of defective class-switch recombination.

T Cell Dysregulation

Many CVID patients exhibit T cell abnormalities including reduced naive CD4+ T cells, expanded CD21low B cells, impaired T cell proliferation, and skewed T helper cell responses. T follicular helper cell dysfunction contributes to impaired germinal center reactions and defective B cell help. ICOS deficiency specifically impairs T cell help for late B cell differentiation and memory B cell generation.

CD4+ T Cell link

T Cell Activation link

Show evidence (2 references)

PMID:12577056 SUPPORT Human Clinical

"we found four of 32 patients to lack ICOS, the "inducible costimulator" on activated T cells, due to an inherited homozygous deletion in the ICOS gene. T cells from these individuals were normal with regard to subset distribution, activation, cytokine production and proliferation. In contrast,..."

Demonstrates that ICOS deficiency causes CVID through impaired T cell costimulation for B cell differentiation, with reduced naive, switched, and memory B cells despite normal T cell subsets.

DOI:10.1007/s10875-023-01618-0 SUPPORT Human Clinical

"Levels of microRNA-34a correlated with 11 proteins such as CXCL9, TNF, and IL10, which were predicted to be biologically connected. Moreover, there was a negative correlation between mir-34 levels and the number of naïve CD4 T cells in CVID."

Demonstrates reduced naive CD4 T cells in CVID correlating with inflammatory markers, supporting T cell dysregulation as a key pathophysiological feature.

Immune Dysregulation and Autoimmunity

Approximately 25-50% of CVID patients develop autoimmune complications, most commonly autoimmune cytopenias (immune thrombocytopenia and autoimmune hemolytic anemia). This reflects a breakdown of peripheral tolerance and defective regulatory T cell function, particularly through the CTLA-4/LRBA checkpoint axis. Expansion of autoreactive CD21low B cells contributes to antibody-mediated autoimmunity.

Regulatory T cell link

Immune Response link

Show evidence (1 reference)

PMID:25213377 SUPPORT Human Clinical

"human CTLA4 haploinsufficiency caused dysregulation of FoxP3(+) regulatory T (Treg) cells, hyperactivation of effector T cells, and lymphocytic infiltration of target organs. Patients also exhibited progressive loss of circulating B cells, associated with an increase of predominantly..."

Shows that CTLA4 haploinsufficiency, found in a subset of CVID patients, causes Treg dysfunction, expansion of autoreactive CD21low B cells, and immune dysregulation, explaining autoimmune manifestations in CVID.

Granulomatous Disease and GLILD

CVID-associated granulomatous and lymphocytic interstitial lung disease (GLILD) involves poorly organized granulomas with abundant T and B cells. Key features include Th1 polarization with elevated IFN-gamma and sIL-2R, B cell abnormalities with elevated BAFF and CD21low B cells, and innate immune alterations including M2 macrophage skewing and neutrophil dysregulation.

B cell link Macrophage link

Inflammatory Response link

Show evidence (1 reference)

DOI:10.1097/aci.0000000000001032 SUPPORT Human Clinical

"Histological analysis shows that T and B cells are abundantly present in the granulomas that are less well organized and are frequently associated with lymphoid hyperplasia. Increased presence of activation markers such as soluble IL-2 receptor (sIL-2R) and IFN-ɣ, suggest increased Th1-cell..."

This 2024 review describes the immunopathology of CVID-associated granulomatous disease, demonstrating T and B cell involvement, Th1 polarization, and BAFF/CD21low B cell expansion.

●

Phenotypes

Blood 6

Hypogammaglobulinemia VERY_FREQUENT Decreased circulating immunoglobulin concentration (HP:0004313)

Show evidence (1 reference)

DOI:10.3390/jcm13061717 SUPPORT Human Clinical

"Common Variable Immunodeficiency (CVID) is a heterogeneous primary immunodeficiency disorder characterised by impaired antibody production, leading to recurrent infections and an increased susceptibility to viral pathogens."

Confirms hypogammaglobulinemia as the defining feature of CVID.

Decreased Circulating IgG VERY_FREQUENT Decreased circulating IgG concentration (HP:0004315)

Decreased Circulating IgA VERY_FREQUENT Decreased circulating IgA concentration (HP:0002720)

Autoimmune Hemolytic Anemia Autoimmune hemolytic anemia (HP:0001890)

Show evidence (1 reference)

PMID:25213377 SUPPORT Human Clinical

"Patient B.I.1, previously diagnosed with common variable immunodeficiency (CVID), had hepatosplenomegaly, autoimmune hemolytic anemia (AIHA), autoimmune thrombocytopenia, pulmonary nodules, and cerebral infiltrative lesions."

Documents autoimmune hemolytic anemia as a feature in a CVID patient with CTLA4 haploinsufficiency.

Autoimmune Thrombocytopenia Autoimmune thrombocytopenia (HP:0001973)

Granulomatous Disease Granulomatosis (HP:0002955)

Show evidence (1 reference)

DOI:10.1097/aci.0000000000001032 SUPPORT Human Clinical

"This review describes the current knowledge on the pathogenesis of granuloma formation in CVID and the biological basis of the current treatment options."

A 2024 review dedicated to granulomatous disease in CVID, confirming it as a major complication.

Cardiovascular 2

Splenomegaly Splenomegaly (HP:0001744)

Lymphadenopathy Lymphadenopathy (HP:0002716)

Digestive 1

CVID Enteropathy Chronic diarrhea (HP:0002028)

Show evidence (1 reference)

DOI:10.1097/aci.0000000000001040 SUPPORT Human Clinical

"Common variable immunodeficiency enteropathy (CVID-E) is a noninfectious complication of CVID caused by chronic inflammation of the gastrointestinal (GI) tract."

Defines CVID enteropathy as a recognized noninfectious gastrointestinal complication; chronic diarrhea is the closest curated HPO phenotype term.

Immune 1

Recurrent Infections VERY_FREQUENT Recurrent infections (HP:0002719)

Show evidence (1 reference)

DOI:10.3390/jcm13061717 SUPPORT Human Clinical

Confirms recurrent infections as a cardinal feature of CVID driven by impaired antibody production.

Respiratory 2

Bronchiectasis Bronchiectasis (HP:0002110)

Granulomatous-Lymphocytic Interstitial Lung Disease Abnormal pulmonary interstitial morphology (HP:0006530)

Show evidence (1 reference)

DOI:10.1097/aci.0000000000001032 SUPPORT Human Clinical

"Our review links the biological context of CVID with granulomatous disease or GLILD to currently prescribed therapies and potential targeted treatments."

Confirms GLILD as a recognized CVID-associated interstitial lung complication that should be represented alongside the existing pathophysiology node.

🧬

Genetic Associations

TNFRSF13B (TACI) Mutations (PREDISPOSING)

Show evidence (1 reference)

PMID:16007086 SUPPORT Human Clinical

"We found that 4 of 19 unrelated individuals with common variable immunodeficiency (CVID) and 1 of 16 individuals with IgA deficiency (IgAD) had a missense mutation in one allele of TNFRSF13B (encoding TACI)."

Landmark study identifying TACI mutations in approximately 20% of CVID patients studied, establishing TACI as a risk factor for CVID.

ICOS Deficiency (CAUSATIVE)

Show evidence (1 reference)

PMID:12577056 SUPPORT Human Clinical

"we found four of 32 patients to lack ICOS, the "inducible costimulator" on activated T cells, due to an inherited homozygous deletion in the ICOS gene."

First identification of ICOS deficiency as a monogenic cause of CVID, demonstrating homozygous ICOS deletion in affected patients.

NFKB1 Haploinsufficiency (CAUSATIVE)

Show evidence (2 references)

PMID:26279205 SUPPORT Human Clinical

"we conclude that the CVID phenotype in these families is caused by NF-κB1 p50 haploinsufficiency."

Identifies NFKB1 haploinsufficiency as a cause of CVID through degradation of the altered protein with loss of p50 transcription factor.

PMID:29477724 SUPPORT Human Clinical

"Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans."

Large-scale study confirming NFKB1 as the most common monogenic cause of CVID in European populations.

CTLA4 Haploinsufficiency (CAUSATIVE)

Show evidence (1 reference)

PMID:25213377 SUPPORT Human Clinical

"We identified germline heterozygous mutations in CTLA4 in subjects with severe immune dysregulation from four unrelated families."

Identifies CTLA4 haploinsufficiency as a cause of CVID-like immune dysregulation with hypogammaglobulinemia, autoimmune cytopenias, and lymphocytic organ infiltration.

LRBA Deficiency (CAUSATIVE)

Show evidence (1 reference)

DOI:10.1097/aci.0000000000000947 SUPPORT Human Clinical

"On the other hand, patients with defects in CTLA-4 or LRBA gene present with life-threatening immune dysregulation, autoimmunity and lymphocytic infiltration of multiple organs."

This 2023 review highlights LRBA defects as a monogenic CVID-like form marked by severe immune dysregulation, autoimmunity, and multisystem organ infiltration.

BAFF-R (TNFRSF13C) Mutations (CAUSATIVE)

CTNNBL1 (Pathogenic Variants)

Show evidence (1 reference)

CGGV:assertion_4e151724-c8a5-4f3e-a7ac-bd0b1d180fae-2022-05-17T160000.000Z SUPPORT Other

ClinGen classifies the CTNNBL1-common variable immunodeficiency gene-disease relationship as limited with autosomal recessive inheritance.

ICOS (Pathogenic Variants)

Show evidence (1 reference)

CGGV:assertion_51864ec9-27d9-4a94-9524-d6828b17361d-2022-11-29T170000.000Z SUPPORT Other

ClinGen classifies the ICOS-common variable immunodeficiency gene-disease relationship as definitive with autosomal recessive inheritance.

TNFSF12 (Pathogenic Variants)

Show evidence (1 reference)

CGGV:assertion_b943345a-024d-401d-a147-470c0ea0381c-2022-07-22T160000.000Z SUPPORT Other

ClinGen classifies the TNFSF12-common variable immunodeficiency gene-disease relationship as limited with autosomal dominant inheritance.

TNFSF13 (Pathogenic Variants)

Show evidence (1 reference)

CGGV:assertion_c181d44b-5c48-441b-95ad-b4d06572596d-2022-09-20T160000.000Z SUPPORT Other

ClinGen classifies the TNFSF13-common variable immunodeficiency gene-disease relationship as limited with autosomal recessive inheritance.

💊

Treatments

Immunoglobulin Replacement Therapy

Action: immunoglobulin replacement therapy Ontology label: Pharmacotherapy NCIT:C15986

Lifelong intravenous (IVIG) or subcutaneous (SCIG) immunoglobulin replacement is the cornerstone of CVID treatment, reducing the frequency and severity of infections.

Show evidence (1 reference)

DOI:10.3390/jcm13061717 SUPPORT Human Clinical

"It assesses the efficacy of prophylactic measures for COVID-19, including vaccination and immunoglobulin replacement therapy, as well as trialled therapies."

Confirms immunoglobulin replacement therapy as a standard treatment modality for CVID patients.

Antibiotic Prophylaxis and Treatment

Action: antibiotic therapy Ontology label: Antibiotic Therapy NCIT:C15620

Prophylactic and therapeutic antibiotics are used to manage recurrent bacterial infections, particularly sinopulmonary infections.

Immunosuppressive Therapy for Autoimmune Complications

Action: immunosuppressive therapy Ontology label: Pharmacotherapy NCIT:C15986

Corticosteroids, rituximab, and other immunosuppressants are used to manage autoimmune cytopenias and granulomatous disease. Treatment selection is increasingly aligned to biological mechanisms: rituximab for B cell hyperplasia and sirolimus for mTOR/Th1 programs.

Show evidence (1 reference)

DOI:10.1097/aci.0000000000001032 SUPPORT Human Clinical

"Therapeutic regimens include glucocorticoids, DMARDs, and biologicals like rituximab."

Confirms the use of glucocorticoids, DMARDs, and rituximab for granulomatous disease in CVID.

Abatacept

Action: Pharmacotherapy NCIT:C15986

Agent: abatacept ↗

Abatacept is a CTLA-4-Ig fusion protein used as targeted immunomodulation for CVID subsets with CTLA4/LRBA-driven immune dysregulation, particularly enteropathy, autoimmunity, and GLILD.

Show evidence (1 reference)

DOI:10.1097/aci.0000000000000947 SUPPORT Human Clinical

"Abatacept, a soluble cytotoxic T lymphocyte antigen 4 (CTLA-4) fusion protein that acts as a costimulation modulator, has been widely implemented for affected patients with good results as bridge treatment."

Supports abatacept as a mechanistically targeted therapy for CTLA4/LRBA-associated CVID-like immune dysregulation.

{ }

Source YAML

click to show

name: Common Variable Immunodeficiency
creation_date: "2026-03-06T00:00:00Z"
updated_date: "2026-04-21T20:43:06Z"
category: Complex
parents:
- Primary Immunodeficiency
- Antibody Deficiency Disorder
disease_term:
  preferred_term: Common Variable Immunodeficiency
  term:
    id: MONDO:0015517
    label: common variable immunodeficiency
description: >-
  Common variable immunodeficiency (CVID) is the most prevalent symptomatic
  primary immunodeficiency, characterized by defective B cell differentiation,
  hypogammaglobulinemia, and failure of antibody production. Patients present
  with recurrent bacterial infections, particularly of the respiratory and
  gastrointestinal tracts, and have increased susceptibility to autoimmune
  manifestations, granulomatous disease, and lymphoproliferative disorders.
  CVID is best understood as an umbrella diagnosis with heterogeneous genetic
  and immunologic etiologies spanning monogenic, digenic, and polygenic models.
pathophysiology:
- name: Defective B Cell Differentiation and Class-Switch Recombination
  description: >-
    The hallmark of CVID is a failure of B cells to differentiate into
    immunoglobulin-secreting plasma cells. Defective class-switch recombination
    leads to impaired production of IgG, IgA, and often IgM. Most patients
    show reduced switched memory B cells (CD27+IgD-IgM-). Defects in B cell
    receptor signaling, BAFF/APRIL axis, and NF-kB signaling all converge
    on impaired germinal center output.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Plasma cell
    term:
      id: CL:0000786
      label: plasma cell
  biological_processes:
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  - preferred_term: Isotype Switching
    term:
      id: GO:0045190
      label: isotype switching
  - preferred_term: B Cell Activation
    term:
      id: GO:0042113
      label: B cell activation
  evidence:
  - reference: DOI:10.3390/jcm13061717
    reference_title: "The Scope and Impact of Viral Infections in Common Variable Immunodeficiency (CVID) and CVID-like Disorders: A Literature Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The pathogenesis of CVID involves complex immunological dysregulation,
      including defects in B cell development, antibody class switching, and
      plasma cell differentiation. These abnormalities contribute to an impaired
      humoral immune response against viral agents, predisposing individuals
      with CVID to a broad range of viral infections.
    explanation: >-
      This 2024 review confirms that CVID pathogenesis centers on defective
      B cell development, class switching, and plasma cell differentiation.
  - reference: PMID:16007086
    reference_title: "TACI is mutant in common variable immunodeficiency and IgA deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      B cells from individuals with TACI mutations expressed TACI but did not
      produce IgG and IgA in response to the TACI ligand APRIL, probably
      reflecting impaired isotype switching.
    explanation: >-
      Demonstrates that TACI mutations in CVID patients lead to impaired
      isotype switching, a key mechanism of defective class-switch recombination.
- name: T Cell Dysregulation
  description: >-
    Many CVID patients exhibit T cell abnormalities including reduced naive
    CD4+ T cells, expanded CD21low B cells, impaired T cell proliferation,
    and skewed T helper cell responses. T follicular helper cell dysfunction
    contributes to impaired germinal center reactions and defective B cell help.
    ICOS deficiency specifically impairs T cell help for late B cell
    differentiation and memory B cell generation.
  cell_types:
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: T Cell Activation
    term:
      id: GO:0042110
      label: T cell activation
  evidence:
  - reference: PMID:12577056
    reference_title: "Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we found four of 32 patients to lack ICOS, the "inducible costimulator"
      on activated T cells, due to an inherited homozygous deletion in the ICOS
      gene. T cells from these individuals were normal with regard to subset
      distribution, activation, cytokine production and proliferation. In
      contrast, naive, switched and memory B cells were reduced.
    explanation: >-
      Demonstrates that ICOS deficiency causes CVID through impaired T cell
      costimulation for B cell differentiation, with reduced naive, switched,
      and memory B cells despite normal T cell subsets.
  - reference: DOI:10.1007/s10875-023-01618-0
    reference_title: "Plasma Levels of mir-34a-5p Correlate with Systemic Inflammation and Low Naïve CD4 T Cells in Common Variable Immunodeficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Levels of microRNA-34a correlated with 11 proteins such as CXCL9, TNF,
      and IL10, which were predicted to be biologically connected. Moreover,
      there was a negative correlation between mir-34 levels and the number of
      naïve CD4 T cells in CVID.
    explanation: >-
      Demonstrates reduced naive CD4 T cells in CVID correlating with
      inflammatory markers, supporting T cell dysregulation as a key
      pathophysiological feature.
- name: Immune Dysregulation and Autoimmunity
  description: >-
    Approximately 25-50% of CVID patients develop autoimmune complications,
    most commonly autoimmune cytopenias (immune thrombocytopenia and autoimmune
    hemolytic anemia). This reflects a breakdown of peripheral tolerance and
    defective regulatory T cell function, particularly through the CTLA-4/LRBA
    checkpoint axis. Expansion of autoreactive CD21low B cells contributes
    to antibody-mediated autoimmunity.
  cell_types:
  - preferred_term: Regulatory T cell
    term:
      id: CL:0000815
      label: regulatory T cell
  biological_processes:
  - preferred_term: Immune Response
    term:
      id: GO:0006955
      label: immune response
  evidence:
  - reference: PMID:25213377
    reference_title: "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      human CTLA4 haploinsufficiency caused dysregulation of FoxP3(+) regulatory
      T (Treg) cells, hyperactivation of effector T cells, and lymphocytic
      infiltration of target organs. Patients also exhibited progressive loss of
      circulating B cells, associated with an increase of predominantly
      autoreactive CD21(lo) B cells and accumulation of B cells in nonlymphoid
      organs.
    explanation: >-
      Shows that CTLA4 haploinsufficiency, found in a subset of CVID patients,
      causes Treg dysfunction, expansion of autoreactive CD21low B cells, and
      immune dysregulation, explaining autoimmune manifestations in CVID.
- name: Granulomatous Disease and GLILD
  description: >-
    CVID-associated granulomatous and lymphocytic interstitial lung disease
    (GLILD) involves poorly organized granulomas with abundant T and B cells.
    Key features include Th1 polarization with elevated IFN-gamma and sIL-2R,
    B cell abnormalities with elevated BAFF and CD21low B cells, and innate
    immune alterations including M2 macrophage skewing and neutrophil
    dysregulation.
  cell_types:
  - preferred_term: B cell
    term:
      id: CL:0000236
      label: B cell
  - preferred_term: Macrophage
    term:
      id: CL:0000235
      label: macrophage
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: DOI:10.1097/aci.0000000000001032
    reference_title: "The biological basis for current treatment strategies for granulomatous disease in common variable immunodeficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Histological analysis shows that T and B cells are abundantly present in
      the granulomas that are less well organized and are frequently associated
      with lymphoid hyperplasia. Increased presence of activation markers such
      as soluble IL-2 receptor (sIL-2R) and IFN-ɣ, suggest increased
      Th1-cell activity. Moreover, B-cell abnormalities are prominent in CVID,
      with elevated IgM, BAFF, and CD21low B cells correlating with
      granulomatous disease progression.
    explanation: >-
      This 2024 review describes the immunopathology of CVID-associated
      granulomatous disease, demonstrating T and B cell involvement, Th1
      polarization, and BAFF/CD21low B cell expansion.
phenotypes:
- name: Hypogammaglobulinemia
  category: Immunologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Hypogammaglobulinemia
    term:
      id: HP:0004313
      label: Decreased circulating immunoglobulin concentration
  evidence:
  - reference: DOI:10.3390/jcm13061717
    reference_title: "The Scope and Impact of Viral Infections in Common Variable Immunodeficiency (CVID) and CVID-like Disorders: A Literature Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common Variable Immunodeficiency (CVID) is a heterogeneous primary
      immunodeficiency disorder characterised by impaired antibody production,
      leading to recurrent infections and an increased susceptibility to viral
      pathogens.
    explanation: >-
      Confirms hypogammaglobulinemia as the defining feature of CVID.
- name: Decreased Circulating IgG
  category: Immunologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Decreased Circulating IgG
    term:
      id: HP:0004315
      label: Decreased circulating IgG concentration
- name: Decreased Circulating IgA
  category: Immunologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Decreased Circulating IgA
    term:
      id: HP:0002720
      label: Decreased circulating IgA concentration
- name: Recurrent Infections
  category: Immunologic
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Recurrent Infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: DOI:10.3390/jcm13061717
    reference_title: "The Scope and Impact of Viral Infections in Common Variable Immunodeficiency (CVID) and CVID-like Disorders: A Literature Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common Variable Immunodeficiency (CVID) is a heterogeneous primary
      immunodeficiency disorder characterised by impaired antibody production,
      leading to recurrent infections and an increased susceptibility to viral
      pathogens.
    explanation: >-
      Confirms recurrent infections as a cardinal feature of CVID driven
      by impaired antibody production.
- name: Bronchiectasis
  category: Respiratory
  phenotype_term:
    preferred_term: Bronchiectasis
    term:
      id: HP:0002110
      label: Bronchiectasis
- name: CVID Enteropathy
  category: Gastrointestinal
  description: >-
    Noninfectious chronic inflammatory gastrointestinal disease in CVID,
    typically manifesting with chronic diarrhea and biopsy evidence of plasma
    cell paucity.
  phenotype_term:
    preferred_term: CVID enteropathy
    term:
      id: HP:0002028
      label: Chronic diarrhea
  evidence:
  - reference: DOI:10.1097/aci.0000000000001040
    reference_title: "Paucity of gastrointestinal plasma cells in common variable immunodeficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Common variable immunodeficiency enteropathy (CVID-E) is a noninfectious
      complication of CVID caused by chronic inflammation of the
      gastrointestinal (GI) tract.
    explanation: >-
      Defines CVID enteropathy as a recognized noninfectious gastrointestinal
      complication; chronic diarrhea is the closest curated HPO phenotype term.
- name: Granulomatous-Lymphocytic Interstitial Lung Disease
  category: Respiratory
  description: >-
    CVID-associated GLILD is a noninfectious interstitial lung complication
    characterized by granulomatous and lymphocytic inflammation.
  phenotype_term:
    preferred_term: granulomatous-lymphocytic interstitial lung disease
    term:
      id: HP:0006530
      label: Abnormal pulmonary interstitial morphology
  evidence:
  - reference: DOI:10.1097/aci.0000000000001032
    reference_title: "The biological basis for current treatment strategies for granulomatous disease in common variable immunodeficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our review links the biological context of CVID with granulomatous
      disease or GLILD to currently prescribed therapies and potential targeted
      treatments.
    explanation: >-
      Confirms GLILD as a recognized CVID-associated interstitial lung
      complication that should be represented alongside the existing
      pathophysiology node.
- name: Splenomegaly
  category: Immunologic
  phenotype_term:
    preferred_term: Splenomegaly
    term:
      id: HP:0001744
      label: Splenomegaly
- name: Lymphadenopathy
  category: Immunologic
  phenotype_term:
    preferred_term: Lymphadenopathy
    term:
      id: HP:0002716
      label: Lymphadenopathy
- name: Autoimmune Hemolytic Anemia
  category: Hematologic
  phenotype_term:
    preferred_term: Autoimmune Hemolytic Anemia
    term:
      id: HP:0001890
      label: Autoimmune hemolytic anemia
  evidence:
  - reference: PMID:25213377
    reference_title: "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patient B.I.1, previously diagnosed with common variable immunodeficiency
      (CVID), had hepatosplenomegaly, autoimmune hemolytic anemia (AIHA),
      autoimmune thrombocytopenia, pulmonary nodules, and cerebral infiltrative
      lesions.
    explanation: >-
      Documents autoimmune hemolytic anemia as a feature in a CVID patient
      with CTLA4 haploinsufficiency.
- name: Autoimmune Thrombocytopenia
  category: Hematologic
  phenotype_term:
    preferred_term: Autoimmune Thrombocytopenia
    term:
      id: HP:0001973
      label: Autoimmune thrombocytopenia
- name: Granulomatous Disease
  category: Immunologic
  phenotype_term:
    preferred_term: Granulomatous Disease
    term:
      id: HP:0002955
      label: Granulomatosis
  evidence:
  - reference: DOI:10.1097/aci.0000000000001032
    reference_title: "The biological basis for current treatment strategies for granulomatous disease in common variable immunodeficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This review describes the current knowledge on the pathogenesis of
      granuloma formation in CVID and the biological basis of the current
      treatment options.
    explanation: >-
      A 2024 review dedicated to granulomatous disease in CVID, confirming
      it as a major complication.
genetic:
- name: TNFRSF13B (TACI) Mutations
  association: PREDISPOSING
  evidence:
  - reference: PMID:16007086
    reference_title: "TACI is mutant in common variable immunodeficiency and IgA deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found that 4 of 19 unrelated individuals with common variable
      immunodeficiency (CVID) and 1 of 16 individuals with IgA deficiency
      (IgAD) had a missense mutation in one allele of TNFRSF13B (encoding
      TACI).
    explanation: >-
      Landmark study identifying TACI mutations in approximately 20% of
      CVID patients studied, establishing TACI as a risk factor for CVID.
- name: ICOS Deficiency
  association: CAUSATIVE
  evidence:
  - reference: PMID:12577056
    reference_title: "Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we found four of 32 patients to lack ICOS, the "inducible costimulator"
      on activated T cells, due to an inherited homozygous deletion in the ICOS
      gene.
    explanation: >-
      First identification of ICOS deficiency as a monogenic cause of CVID,
      demonstrating homozygous ICOS deletion in affected patients.
- name: NFKB1 Haploinsufficiency
  association: CAUSATIVE
  evidence:
  - reference: PMID:26279205
    reference_title: "Haploinsufficiency of the NF-κB1 Subunit p50 in Common Variable Immunodeficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we conclude that the CVID phenotype in these families is caused by
      NF-κB1 p50 haploinsufficiency.
    explanation: >-
      Identifies NFKB1 haploinsufficiency as a cause of CVID through
      degradation of the altered protein with loss of p50 transcription factor.
  - reference: PMID:29477724
    reference_title: "Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the
      most common monogenic cause of common variable immunodeficiency in
      Europeans.
    explanation: >-
      Large-scale study confirming NFKB1 as the most common monogenic cause
      of CVID in European populations.
- name: CTLA4 Haploinsufficiency
  association: CAUSATIVE
  evidence:
  - reference: PMID:25213377
    reference_title: "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We identified germline heterozygous mutations in CTLA4 in subjects with
      severe immune dysregulation from four unrelated families.
    explanation: >-
      Identifies CTLA4 haploinsufficiency as a cause of CVID-like immune
      dysregulation with hypogammaglobulinemia, autoimmune cytopenias, and
      lymphocytic organ infiltration.
- name: LRBA Deficiency
  association: CAUSATIVE
  evidence:
  - reference: DOI:10.1097/aci.0000000000000947
    reference_title: "Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      On the other hand, patients with defects in CTLA-4 or LRBA gene present
      with life-threatening immune dysregulation, autoimmunity and lymphocytic
      infiltration of multiple organs.
    explanation: >-
      This 2023 review highlights LRBA defects as a monogenic CVID-like form
      marked by severe immune dysregulation, autoimmunity, and multisystem
      organ infiltration.
- name: BAFF-R (TNFRSF13C) Mutations
  association: CAUSATIVE
- name: CTNNBL1
  gene_term:
    preferred_term: CTNNBL1
    term:
      id: hgnc:15879
      label: CTNNBL1
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_4e151724-c8a5-4f3e-a7ac-bd0b1d180fae-2022-05-17T160000.000Z
    reference_title: "CTNNBL1 / common variable immunodeficiency (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CTNNBL1 | HGNC:15879 | common variable immunodeficiency | MONDO:0015517 | AR | Limited"
    explanation: ClinGen classifies the CTNNBL1-common variable immunodeficiency gene-disease relationship as limited with autosomal recessive inheritance.
- name: ICOS
  gene_term:
    preferred_term: ICOS
    term:
      id: hgnc:5351
      label: ICOS
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_51864ec9-27d9-4a94-9524-d6828b17361d-2022-11-29T170000.000Z
    reference_title: "ICOS / common variable immunodeficiency (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICOS | HGNC:5351 | common variable immunodeficiency | MONDO:0015517 | AR | Definitive"
    explanation: ClinGen classifies the ICOS-common variable immunodeficiency gene-disease relationship as definitive with autosomal recessive inheritance.
- name: TNFSF12
  gene_term:
    preferred_term: TNFSF12
    term:
      id: hgnc:11927
      label: TNFSF12
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_b943345a-024d-401d-a147-470c0ea0381c-2022-07-22T160000.000Z
    reference_title: "TNFSF12 / common variable immunodeficiency (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TNFSF12 | HGNC:11927 | common variable immunodeficiency | MONDO:0015517 | AD | Limited"
    explanation: ClinGen classifies the TNFSF12-common variable immunodeficiency gene-disease relationship as limited with autosomal dominant inheritance.
- name: TNFSF13
  gene_term:
    preferred_term: TNFSF13
    term:
      id: hgnc:11928
      label: TNFSF13
  association: Pathogenic Variants
  evidence:
  - reference: CGGV:assertion_c181d44b-5c48-441b-95ad-b4d06572596d-2022-09-20T160000.000Z
    reference_title: "TNFSF13 / common variable immunodeficiency (Limited)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "TNFSF13 | HGNC:11928 | common variable immunodeficiency | MONDO:0015517 | AR | Limited"
    explanation: ClinGen classifies the TNFSF13-common variable immunodeficiency gene-disease relationship as limited with autosomal recessive inheritance.
treatments:
- name: Immunoglobulin Replacement Therapy
  description: >-
    Lifelong intravenous (IVIG) or subcutaneous (SCIG) immunoglobulin
    replacement is the cornerstone of CVID treatment, reducing the frequency
    and severity of infections.
  treatment_term:
    preferred_term: immunoglobulin replacement therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: DOI:10.3390/jcm13061717
    reference_title: "The Scope and Impact of Viral Infections in Common Variable Immunodeficiency (CVID) and CVID-like Disorders: A Literature Review"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It assesses the efficacy of prophylactic measures for COVID-19, including
      vaccination and immunoglobulin replacement therapy, as well as trialled
      therapies.
    explanation: >-
      Confirms immunoglobulin replacement therapy as a standard treatment
      modality for CVID patients.
- name: Antibiotic Prophylaxis and Treatment
  description: >-
    Prophylactic and therapeutic antibiotics are used to manage recurrent
    bacterial infections, particularly sinopulmonary infections.
  treatment_term:
    preferred_term: antibiotic therapy
    term:
      id: NCIT:C15620
      label: Antibiotic Therapy
- name: Immunosuppressive Therapy for Autoimmune Complications
  description: >-
    Corticosteroids, rituximab, and other immunosuppressants are used
    to manage autoimmune cytopenias and granulomatous disease. Treatment
    selection is increasingly aligned to biological mechanisms: rituximab
    for B cell hyperplasia and sirolimus for mTOR/Th1 programs.
  treatment_term:
    preferred_term: immunosuppressive therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: DOI:10.1097/aci.0000000000001032
    reference_title: "The biological basis for current treatment strategies for granulomatous disease in common variable immunodeficiency"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Therapeutic regimens include glucocorticoids, DMARDs, and biologicals
      like rituximab.
    explanation: >-
      Confirms the use of glucocorticoids, DMARDs, and rituximab for
      granulomatous disease in CVID.
- name: Abatacept
  description: >-
    Abatacept is a CTLA-4-Ig fusion protein used as targeted immunomodulation
    for CVID subsets with CTLA4/LRBA-driven immune dysregulation, particularly
    enteropathy, autoimmunity, and GLILD.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: abatacept
      term:
        id: NCIT:C28898
        label: Abatacept
  evidence:
  - reference: DOI:10.1097/aci.0000000000000947
    reference_title: "Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Abatacept, a soluble cytotoxic T lymphocyte antigen 4 (CTLA-4) fusion
      protein that acts as a costimulation modulator, has been widely
      implemented for affected patients with good results as bridge treatment.
    explanation: >-
      Supports abatacept as a mechanistically targeted therapy for
      CTLA4/LRBA-associated CVID-like immune dysregulation.
datasets:

📚

References & Deep Research

Deep Research

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 32 citations 2026-03-06T04:06:20.239384

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: Common Variable Immunodeficiency
MONDO ID: (if available)
Category: Complex

Research Objectives

Please provide a comprehensive research report on the pathophysiology of Common Variable Immunodeficiency. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Comprehensive Research Report: Common Variable Immunodeficiency (CVID) Pathophysiology (Molecular/Cellular)

Disease identifiers and classification

Disease name: Common variable immunodeficiency (CVID)
MONDO ID: MONDO:0015517 (“common variable immunodeficiency”) as represented in Open Targets disease mapping ().
Category: Complex/heterogeneous inborn error of immunity (IEI) syndrome; increasingly partitioned into (i) polygenic/multifactorial “CVID” and (ii) monogenic “CVID-like” disorders (alhakim2024thescopeand pages 2-4).

1. Key concepts and definitions (current understanding)

Definition (clinical-immunologic)

CVID is defined by hypogammaglobulinemia (IgG ≥2 SD below age-adjusted mean, with low IgA and/or IgM), poor vaccine responses, and exclusion of secondary causes, reflecting failure to generate effective humoral immunity (sircana2023commonvariableimmunodeficiency pages 3-4). Mechanistically, it is centered on failure of B-cell terminal differentiation in germinal centers, leading to reduced plasma cells and memory B cells and inadequate antibody production (sircana2023commonvariableimmunodeficiency pages 3-4).

Epidemiology and baseline quantitative features

Estimated prevalence/incidence: commonly reported as ~1:25,000–1:50,000 (sircana2023commonvariableimmunodeficiency pages 3-4, barbati2024monogeniccommonvariable pages 1-5) and also described as ~1 in 20,000–50,000 (cunninghamrundles2024commonvariableimmunodeficiency pages 1-2).
Hypogammaglobulinemia depth: in two large cohorts, 85–94% of cases had IgG <4.5 g/L (alhakim2024thescopeand pages 2-4).
Familial aggregation: familial inheritance of CVID/IgA deficiency is reported at ~20% (alhakim2024thescopeand pages 2-4), with familial clustering estimates ~5–25% in other summaries (sircana2023commonvariableimmunodeficiency pages 3-4).

“CVID+” immune dysregulation endotype

Beyond infection susceptibility, a major conceptual advance is routine recognition of an “immune dysregulation” phenotype (often termed CVID+) with inflammatory/autoimmune complications: - >50% of patients have inflammatory and/or autoimmune complications (“CVID+”) and ~25% have autoimmunity (alhakim2024thescopeand pages 2-4). - In a cohort of 408 CVID patients, 122 (30%) had hematologic autoimmune manifestations (ITP, AIHA, Evans syndrome, neutropenia) (cunninghamrundles2024commonvariableimmunodeficiency pages 1-2).

2. Core pathophysiology (molecular and cellular mechanisms)

CVID is best understood as a syndrome of convergent failures in germinal-center (GC)–dependent humoral immunity and peripheral tolerance, arising from diverse genetic and non-genetic perturbations.

2.1 B-cell developmental/GC output failure (central axis)

A core feature is defective generation of class-switched memory B cells and plasma cells, reflecting impaired GC maturation and/or post-GC survival. - Reviews emphasize impaired differentiation into class-switched memory B cells and plasma cells, with reductions in mucosal sites and bone marrow noted in CVID cohorts (alhakim2024thescopeand pages 2-4). - A foundational mechanistic framing is “failure of B-cell terminal differentiation in germinal centers” with reduced plasma cells/memory B cells (sircana2023commonvariableimmunodeficiency pages 3-4).

2.2 BAFF/APRIL–TACI axis and NF-κB signaling (B-cell survival and plasma cell differentiation)

The BAFF/APRIL system is repeatedly implicated in CVID pathophysiology, connecting survival signaling with plasma cell generation and tolerance. - BAFF/APRIL bind overlapping receptors, and TACI activation triggers NFAT, NF-κB, and AP‑1 to promote antibody production and plasma cell differentiation (peng2023commonvariableimmunodeficiency pages 7-9). - TNFRSF13B (TACI) variants are associated with CVID/sIgAD; heterozygous variants can promote autoimmunity by preserving autoreactive B cells responsive to Tfh stimulation (peng2023commonvariableimmunodeficiency pages 7-9). - Population genetics highlight incomplete penetrance: common TNFRSF13B alleles (e.g., C104R, A181E) can abrogate signaling yet have substantial asymptomatic carriage (∼25% asymptomatic carriers in some family-based observations; allele frequency ~0.5–0.7% in Europeans) (peng2023commonvariableimmunodeficiency pages 7-9). - NF-κB pathway lesions are central; both canonical and non-canonical NF-κB pathways are key to B-cell development/function (peng2023commonvariableimmunodeficiency pages 9-10). NFKB1 loss-of-function/haploinsufficiency is linked to CVID and described as “the most common monogenic cause” in Europeans (peng2023commonvariableimmunodeficiency pages 22-23).

2.3 PI3Kδ–AKT–mTOR pathway dysregulation (APDS and GC disruption)

Hyperactive PI3K signaling provides a clear mechanistic bridge between signaling gain-of-function, GC collapse, and CVID-like antibody deficiency. - In APDS1 (PIK3CD GOF), disease includes “uncontrolled lymphocyte proliferation, accelerated T cell maturation and senescence, and impaired B cell maturation” (direct quote) (peng2023commonvariableimmunodeficiency pages 9-10). - Hyperactive PI3K signaling can disrupt GC structure and interfere with CSR (class-switch recombination), yielding a hyper-IgM–like phenotype (peng2023commonvariableimmunodeficiency pages 9-10).

2.4 T-cell help and tolerance checkpoints (Tfh/Treg/CTLA-4–LRBA)

Although classified as an antibody deficiency, a substantial subset involves impaired or dysregulated T-cell help and tolerance. - T-cell defects are reported in ~one-third of CVID cases (alhakim2024thescopeand pages 2-4). - Defects in central and peripheral tolerance pathways and dysregulated Tfh responses can impair CSR/memory B-cell generation (peng2023commonvariableimmunodeficiency pages 12-13). - CTLA4 haploinsufficiency and LRBA deficiency exemplify a mechanism where defective inhibitory costimulation and altered CTLA-4 trafficking produce hypogammaglobulinemia with autoimmunity/organ infiltration (enteropathy, interstitial lung disease) (peng2023commonvariableimmunodeficiency pages 13-15, tessarin2023monogenicformsof pages 4-5). LRBA mutations (identified in ~140 patients) can cause functional CTLA-4 loss, autophagy-related abnormalities (reduced LC3 localization), and failure of B cells to form plasmablasts; marked clinical responses to CTLA-4–Ig (abatacept) are reported (peng2023commonvariableimmunodeficiency pages 13-15).

2.5 Additional mechanistic routes (DNA repair, transcriptional regulation, organelle/trafficking)

CVID encompasses many routes beyond classical BCR signaling. - CSR/SHM defects can occur via AID trafficking perturbations (e.g., CTNNBL1 effect on AID nuclear translocation) leading to impaired SHM and inefficient GC reactions, with risk of autoreactive clones and autoimmunity (peng2023commonvariableimmunodeficiency pages 12-13). - Transcriptional regulators (e.g., BACH2 haploinsufficiency) disrupt T/B specification and CSR/plasmablast differentiation (peng2023commonvariableimmunodeficiency pages 13-15). - Broader “organelle/trafficking” mechanisms (e.g., SEC61A1, SH3KBP1, DEF6, SAMD9) affect ER homeostasis, calcium flux, mitochondrial health and receptor signaling and can produce CVID-like phenotypes with autoimmunity/autoinflammation (peng2023commonvariableimmunodeficiency pages 13-15).

3. Key molecular players (genes/proteins, cells, tissues, chemicals)

3.1 Genes/Proteins (HGNC symbols)

CVID and CVID-like disorders have substantial genetic heterogeneity spanning B-cell intrinsic and immune regulatory genes.

High-confidence/commonly implicated (examples): - NF-κB signaling: NFKB1, NFKB2 (peng2023commonvariableimmunodeficiency pages 22-23, peng2023commonvariableimmunodeficiency pages 9-10). - BAFF/APRIL/TACI axis: TNFRSF13B (TACI), TNFRSF13C (BAFF-R) (peng2023commonvariableimmunodeficiency pages 7-9, sircana2023commonvariableimmunodeficiency pages 3-4, sircana2023commonvariableimmunodeficiency pages 4-6). - BCR co-receptors: CD19, CD81, MS4A1 (CD20), CR2 (CD21) (alhakim2024thescopeand pages 2-4, sircana2023commonvariableimmunodeficiency pages 3-4). - PI3K pathway: PIK3CD, PIK3R1, PTEN (peng2023commonvariableimmunodeficiency pages 9-10, tessarin2023monogenicformsof pages 1-2). - Immune regulation: CTLA4, LRBA (peng2023commonvariableimmunodeficiency pages 13-15, tessarin2023monogenicformsof pages 4-5). - Transcription/regulatory: IKZF1, BACH2, STAT3, STAT1, SOCS1 (peng2023commonvariableimmunodeficiency pages 12-13, peng2023commonvariableimmunodeficiency pages 9-10).

Recent (2024) pediatric cohort genetic yield and gene list: In a pediatric CVID cohort (n=32), variants were identified in 17 (53%), including SLC39A7, PRKCD, STAT3, NFKB1, PIK3R1, PLCG2, RFXANK, PRKDC, TNFRSF13B, and novel SPI1 and NFKB1 variants (barbati2024monogeniccommonvariable pages 1-5).

Open Targets disease–gene associations: Open Targets lists top CVID-associated targets including TNFRSF13B, LRBA, IKZF1, NFKB2, ICOS, and CD19 (). (Note: Open Targets is an evidence integration resource; mechanistic interpretation still relies on primary/review literature.)

3.2 Chemical entities / therapeutics (CHEBI-relevant entities)

While CVID is not typically “metabolic,” small molecules and biologics are directly relevant via pathway-targeted therapy: - Abatacept (CTLA-4–Ig fusion protein): used as targeted immunomodulation in CTLA-4 haploinsufficiency / LRBA deficiency, with reported high efficacy for chronic enteropathy and lymphoproliferation and variable results for cytopenias/neurologic features; for GLILD, full/partial resolution reported in up to ~70% (tessarin2023monogenicformsof pages 4-5). A case report in a CVID patient with CTLA4/LRBA variants described rapid regression of clinical/lab findings and weight gain after abatacept initiation (). - PI3K inhibitors (APDS): direct PI3K inhibitor approval and clinical improvement in APDS is highlighted in recent reviews (tessarin2023monogenicformsof pages 1-2, tessarin2023monogenicformsof pages 4-5). - Sirolimus (mTOR inhibitor): reported benefit in some immune dysregulation settings to enhance Treg responses (tessarin2023monogenicformsof pages 4-5). - Immunoglobulin replacement therapy (IgRT; IVIG/SCIG): mainstay therapy that reduces infectious episode rate/severity (tessarin2023monogenicformsof pages 1-2, cunninghamrundles2024commonvariableimmunodeficiency pages 1-2).

3.3 Cell types (Cell Ontology; CL terms suggested)

Key affected or mechanistically implicated immune cell types include: - B cell (CL:0000236) and differentiation states: naïve B cell, memory B cell, class-switched memory B cell, plasmablast, plasma cell (central in terminal differentiation failure) (sircana2023commonvariableimmunodeficiency pages 3-4, alhakim2024thescopeand pages 2-4). - T follicular helper (Tfh) cell (CL:0002057) and regulatory T cell (Treg; CL:0000815): dysregulated help/tolerance links to failed CSR and autoimmunity (peng2023commonvariableimmunodeficiency pages 12-13, peng2023commonvariableimmunodeficiency pages 13-15, alhakim2024thescopeand pages 2-4). - Natural killer cell (CL:0000623): NK defects are discussed in CVID-like phenotypes such as NFKB2-mutated disease (peng2023commonvariableimmunodeficiency pages 22-23) and broader CVID heterogeneity includes NK involvement (alhakim2024thescopeand pages 2-4).

3.4 Anatomical locations (UBERON suggested)

Key sites where the pathophysiology manifests: - Secondary lymphoid organs (UBERON:0002106): lymph nodes (UBERON:0000029), spleen (UBERON:0002106) as germinal center sites supporting CSR and GC output (sircana2023commonvariableimmunodeficiency pages 3-4). - Bone marrow (UBERON:0002371): plasma cell survival/maintenance; reductions in plasma cells noted (alhakim2024thescopeand pages 2-4). - Gastrointestinal tract (e.g., small intestine UBERON:0002108; colon UBERON:0001155; stomach UBERON:0000945): CVID enteropathy is associated with plasma-cell paucity across much of the GI tract (except esophagus) (marsden2024paucityofgastrointestinal pages 1-2). - Lung (UBERON:0002048): granulomatous-lymphocytic interstitial lung disease (GLILD) is part of immune dysregulation phenotypes responsive in some cases to abatacept (tessarin2023monogenicformsof pages 4-5).

4. Biological processes and pathways (GO-oriented annotation candidates)

Below are GO-aligned biological processes strongly supported by the cited literature as disrupted in CVID/CVID-like disease: - B cell differentiation / plasma cell differentiation (GO:0030183; GO:0002314) (sircana2023commonvariableimmunodeficiency pages 3-4, alhakim2024thescopeand pages 2-4). - Immunoglobulin production (GO:0002377) and humoral immune response (GO:0006959) (sircana2023commonvariableimmunodeficiency pages 3-4, alhakim2024thescopeand pages 2-4). - Immunoglobulin class switch recombination (GO:0042167) and somatic hypermutation of immunoglobulin genes (GO:0016446) (peng2023commonvariableimmunodeficiency pages 12-13, peng2023commonvariableimmunodeficiency pages 9-10). - NF-κB signaling (GO:0043122) (peng2023commonvariableimmunodeficiency pages 22-23, peng2023commonvariableimmunodeficiency pages 9-10). - Phosphatidylinositol 3-kinase signaling / AKT-mTOR signaling (GO:0014065; GO:0032008) (peng2023commonvariableimmunodeficiency pages 9-10, tessarin2023monogenicformsof pages 1-2). - T cell co-stimulation / negative regulation of T cell activation (GO:0050863; GO:0050868) (CTLA-4/LRBA axis) (peng2023commonvariableimmunodeficiency pages 13-15, tessarin2023monogenicformsof pages 4-5). - Immune tolerance / regulation of autoimmunity (broadly supported conceptually by tolerance gene involvement and autoimmune enrichment) (peng2023commonvariableimmunodeficiency pages 12-13, alhakim2024thescopeand pages 2-4, cunninghamrundles2024commonvariableimmunodeficiency pages 1-2).

5. Cellular components (GO-CC candidates)

Literature-supported cellular compartments where key pathogenic processes occur include: - Germinal center microenvironment (anatomical/functional compartment; mechanistically central to CSR/SHM and selection) (sircana2023commonvariableimmunodeficiency pages 3-4, peng2023commonvariableimmunodeficiency pages 12-13). - Plasma cell niches in bone marrow and mucosa (alhakim2024thescopeand pages 2-4). - Cell surface receptor complexes (BCR co-receptors CD19/CD81; costimulatory CTLA-4) (alhakim2024thescopeand pages 2-4, peng2023commonvariableimmunodeficiency pages 13-15). - Endomembrane trafficking compartments relevant to CTLA-4/LRBA trafficking and organelle/ER homeostasis in some monogenic forms (peng2023commonvariableimmunodeficiency pages 13-15).

6. Disease progression: mechanistic sequence (model)

A practical progression model consistent with current reviews is: 1. Predisposition/initiating defects: inherited or de novo variants affecting B-cell activation/survival (NF-κB; BAFF/APRIL/TACI), GC help and regulation (ICOS, Tfh/Treg axis; CTLA4/LRBA), or signaling/metabolic checkpoints (PI3Kδ/AKT/mTOR) (peng2023commonvariableimmunodeficiency pages 7-9, peng2023commonvariableimmunodeficiency pages 9-10, peng2023commonvariableimmunodeficiency pages 13-15). 2. Germinal center failure or mis-selection: impaired CSR/SHM, altered selection thresholds, and reduced generation of long-lived plasma cells/switched memory B cells (peng2023commonvariableimmunodeficiency pages 12-13, sircana2023commonvariableimmunodeficiency pages 3-4, peng2023commonvariableimmunodeficiency pages 9-10). 3. Hypogammaglobulinemia and impaired vaccine responses: reduced effective antibody titers, recurrent infections, and persistent antigenic stimulation (alhakim2024thescopeand pages 2-4, sircana2023commonvariableimmunodeficiency pages 3-4). 4. Immune dysregulation amplification (“CVID+”): chronic inflammation, breakdown of tolerance, autoimmunity, lymphoproliferation, organ infiltration (enteropathy, lung disease), and increased morbidity/mortality in severe subsets (alhakim2024thescopeand pages 2-4, cunninghamrundles2024commonvariableimmunodeficiency pages 1-2, tessarin2023monogenicformsof pages 4-5).

7. Phenotypic manifestations and mechanism links (HP-oriented)

Selected phenotype associations (HP terms suggested) grounded in the evidence: - Hypogammaglobulinemia (HP:0004313) and recurrent infections (HP:0002719) arise from impaired plasma cell/memory B-cell output and reduced Ig levels (alhakim2024thescopeand pages 2-4, sircana2023commonvariableimmunodeficiency pages 3-4). - Autoimmune cytopenias (e.g., immune thrombocytopenia HP:0001891; autoimmune hemolytic anemia HP:0001890): observed in 30% (122/408) in one cohort, reflecting immune dysregulation/tolerance loss (cunninghamrundles2024commonvariableimmunodeficiency pages 1-2). - Enteropathy / chronic diarrhea (HP:0002028): immune-mediated enteropathy is a hallmark of CTLA4/LRBA dysregulation subsets and broader CVID-E; GI biopsies frequently show plasma-cell paucity (tessarin2023monogenicformsof pages 4-5, marsden2024paucityofgastrointestinal pages 1-2). - Interstitial lung disease / GLILD (HP:0006530): part of immune dysregulation; abatacept responses reported in some cohorts (tessarin2023monogenicformsof pages 4-5).

8. Recent developments (prioritizing 2023–2024)

8.1 Genetics: increasing recognition of monogenic drivers and stratification tools

Recent summaries emphasize that while earlier estimates suggested 2–10% monogenic causes, newer genomic analyses identify monogenic causes in ~20–50% of CVID/CVID-like cases, and monogenic CVID-like entities are increasingly separated from “true CVID” (alhakim2024thescopeand pages 2-4).
In hematology-focused CVID cohorts, monogenic etiologies are now estimated at ~25–30%, with 43% of patients with hematologic autoimmunity (53/122) having one or more genetic mutations considered related to the immune defect (cunninghamrundles2024commonvariableimmunodeficiency pages 1-2).
A 2024 pediatric cohort (n=32) achieved 53% gene-variant identification and proposed a clinical/immunologic scoring system (Mo-CVID score) to prioritize genetic work-up, highlighting higher yield in early onset, positive family history, autoimmunity, lymphoproliferation, and specific immunologic alterations (barbati2024monogeniccommonvariable pages 1-5).

8.2 Diagnostic yield of sequencing in PID (generalizable implementation evidence)

A 2024 meta-analysis in suspected PIDs (not CVID-specific) provides implementable expectations for NGS: - Across 29 studies and 5,847 patients, pooled NGS diagnostic detection rate was 42% (95% CI 0.29–0.54) (chen2024diagnosticyieldof pages 1-3). - Yield was higher with a family history (58%) vs none (33%) (chen2024diagnosticyieldof pages 1-3). This supports real-world adoption of NGS/WES/WGS in antibody deficiency evaluation pathways, especially in familial/early-onset/complex phenotypes (chen2024diagnosticyieldof pages 1-3, barbati2024monogeniccommonvariable pages 1-5).

8.3 Targeted therapies: pathway-directed treatment for CVID-like immune dysregulation

2023–2024 reviews highlight increasing implementation of abatacept for CTLA4/LRBA-associated immune dysregulation and PI3K inhibitors for APDS (tessarin2023monogenicformsof pages 1-2, tessarin2023monogenicformsof pages 4-5).
A 2023 case report describes abatacept benefit in a patient with severe immune-mediated enteropathy and CTLA4/LRBA variants after a prior CVID diagnosis ().

8.4 GI pathophysiology: standardizing plasma-cell paucity metrics in CVID enteropathy

A 2024 systematic review of GI plasma cells proposes standardized quantification: - Plasma cell paucity is reported across studies in ~50–90% of CVID enteropathy biopsies (marsden2024paucityofgastrointestinal pages 1-2). - Proposed conservative definitions: <10 plasma cells/HPF at 40×, or 1–5% of mononuclear cells, recorded across ≥3 sections and ≥2 biopsies (marsden2024paucityofgastrointestinal pages 1-2, marsden2024paucityofgastrointestinal pages 5-7). - Colon biopsies show paucity/absence in ~60–85% in most studies; IgA+ plasma cells are frequently most reduced (marsden2024paucityofgastrointestinal pages 3-5).

9. Current applications and real-world implementations

9.1 Standard of care

Immunoglobulin replacement therapy (IgRT) (IVIG/SCIG) is the “mainstay,” with evidence that it reduces infectious episode rates and severity (tessarin2023monogenicformsof pages 1-2) and is described as standard management when antibody production is insufficient (cunninghamrundles2024commonvariableimmunodeficiency pages 1-2).

9.2 Precision medicine in monogenic CVID-like disease

Abatacept (CTLA-4–Ig) is “widely implemented” as bridge therapy in CTLA-4/LRBA defects with good results in key inflammatory manifestations (tessarin2023monogenicformsof pages 1-2, tessarin2023monogenicformsof pages 4-5).
Direct PI3K inhibitors have been approved for APDS and show encouraging clinical/immunological control in that defined subgroup (tessarin2023monogenicformsof pages 1-2, tessarin2023monogenicformsof pages 4-5).
Sirolimus is described as beneficial in some settings to enhance T-reg responses (tessarin2023monogenicformsof pages 4-5).

9.3 Diagnostic implementation: integrating immunophenotype + genomics

The 2024 pediatric Mo-CVID work and 2024 PID sequencing meta-analysis both support structured criteria (clinical and immunologic) to prioritize and interpret NGS/WES in clinical practice (barbati2024monogeniccommonvariable pages 1-5, chen2024diagnosticyieldof pages 1-3).

10. Expert opinions / authoritative synthesis (review-derived analysis)

A central interpretive position is that “CVID” is an umbrella phenotype with “incredible diversity of pathophysiological mechanisms,” where genotyping is increasingly necessary to resolve distinct disease entities and guide targeted therapy (peng2023commonvariableimmunodeficiency pages 12-13, alhakim2024thescopeand pages 2-4).
Mechanistically, authoritative reviews emphasize convergent failure of GC outputs via disrupted NF-κB, PI3K/AKT/mTOR, and BAFF/APRIL/TACI signaling, plus immune regulatory lesions (CTLA4/LRBA) that produce combined antibody deficiency and organ-specific inflammation (peng2023commonvariableimmunodeficiency pages 7-9, peng2023commonvariableimmunodeficiency pages 9-10, peng2023commonvariableimmunodeficiency pages 13-15, tessarin2023monogenicformsof pages 4-5).

Structured knowledge-base elements

Pathophysiology description (knowledge-base ready)

CVID is a heterogeneous IEI syndrome characterized by hypogammaglobulinemia and impaired vaccine responses due to failure of germinal center–dependent B-cell terminal differentiation and reduced production/maintenance of class-switched memory B cells and plasma cells. Pathogenic mechanisms converge on (i) B-cell survival/differentiation signaling (BAFF/APRIL/TACI and NF-κB), (ii) GC organization and CSR/SHM (including PI3Kδ hyperactivation and AID-related mechanisms), and (iii) immune tolerance/checkpoint regulation (CTLA-4/LRBA and related Tfh/Treg dysregulation), leading not only to infections but frequently to immune dysregulation (autoimmunity, lymphoproliferation, enteropathy, and interstitial lung disease) in a substantial fraction of patients (peng2023commonvariableimmunodeficiency pages 7-9, sircana2023commonvariableimmunodeficiency pages 3-4, peng2023commonvariableimmunodeficiency pages 9-10, peng2023commonvariableimmunodeficiency pages 13-15, alhakim2024thescopeand pages 2-4, cunninghamrundles2024commonvariableimmunodeficiency pages 1-2, marsden2024paucityofgastrointestinal pages 1-2).

Gene/protein annotations (HGNC; representative set)

NFKB1, NFKB2 — NF-κB signaling; monogenic CVID-like disease; NFKB1 described as a common monogenic cause (peng2023commonvariableimmunodeficiency pages 22-23, peng2023commonvariableimmunodeficiency pages 9-10).
TNFRSF13B (TACI), TNFRSF13C (BAFF-R) — BAFF/APRIL signaling; association with CVID/sIgAD and autoimmunity risk in some carriers (peng2023commonvariableimmunodeficiency pages 7-9, sircana2023commonvariableimmunodeficiency pages 4-6).
PIK3CD, PIK3R1 — PI3Kδ pathway; APDS with CSR/GC disruption and CVID-like phenotype; PI3K inhibitors approved for APDS (peng2023commonvariableimmunodeficiency pages 9-10, tessarin2023monogenicformsof pages 1-2, tessarin2023monogenicformsof pages 4-5).
CTLA4, LRBA — immune checkpoint/trafficking; immune dysregulation with antibody deficiency; abatacept widely used (peng2023commonvariableimmunodeficiency pages 13-15, tessarin2023monogenicformsof pages 4-5).
ICOS — T-cell costimulation and GC Tfh help; included among key CVID genes (alhakim2024thescopeand pages 2-4).

GO biological process candidates (selected)

Immunoglobulin class switch recombination; somatic hypermutation; B-cell differentiation; plasma cell differentiation; NF-κB signaling; PI3K/AKT/mTOR signaling; regulation of T-cell activation/co-stimulation (peng2023commonvariableimmunodeficiency pages 12-13, peng2023commonvariableimmunodeficiency pages 7-9, peng2023commonvariableimmunodeficiency pages 9-10, peng2023commonvariableimmunodeficiency pages 13-15).

Cell types (CL candidates)

B cell, plasma cell, T follicular helper cell, regulatory T cell, natural killer cell (alhakim2024thescopeand pages 2-4, peng2023commonvariableimmunodeficiency pages 13-15).

Anatomical locations (UBERON candidates)

Lymph node/spleen (germinal centers), bone marrow, small intestine/colon/stomach, lung (alhakim2024thescopeand pages 2-4, sircana2023commonvariableimmunodeficiency pages 3-4, marsden2024paucityofgastrointestinal pages 3-5, marsden2024paucityofgastrointestinal pages 1-2).

Chemical entities (selected)

Abatacept; PI3K inhibitors (APDS); sirolimus; immunoglobulin replacement products (tessarin2023monogenicformsof pages 1-2, tessarin2023monogenicformsof pages 4-5).

Evidence tables

Mechanistic Theme	Key Cells / Tissues	Key Pathways / Molecules	Representative Genes	Key Evidence / Statistics
B-cell Maturation & Survival Defects	B cells (Bone marrow, Lymph nodes), Plasma cells	BAFF/APRIL/TACI signaling; NF-κB signaling (canonical/non-canonical)	TNFRSF13B (TACI), TNFRSF13C (BAFF-R), NFKB1, NFKB2, CD19, CD20, CD21, CD81	• 85–94% of cases show IgG <4.5 g/L (alhakim2024thescopeand pages 2-4). • TACI/BAFF-R defects found in 20–30% of patients (sircana2023commonvariableimmunodeficiency pages 4-6). • NFKB1 LOF variants are a common monogenic cause (peng2023commonvariableimmunodeficiency pages 22-23).
Class-Switch & Plasma Cell Differentiation	Germinal Center B cells, Plasma cells	CD40/CD40L; ICOS/ICOS-L; Cytokine signaling (IL-21, IL-10); Transcription factors	ICOS, CD40LG, AICDA, STAT3, BACH2, PRKCD, IKZF1	• Failure of terminal differentiation into memory B cells and plasma cells is central (alhakim2024thescopeand pages 2-4, sircana2023commonvariableimmunodeficiency pages 3-4). • Gastrointestinal plasma cell paucity observed in 50–90% of CVID enteropathy biopsies (marsden2024paucityofgastrointestinal pages 2-3, marsden2024paucityofgastrointestinal pages 1-2).
Immune Dysregulation & Tolerance Loss	Regulatory T cells (Tregs), Tfh cells, Autoreactive B cells	CTLA-4 checkpoint; Transendocytosis; Autophagy	CTLA4, LRBA, FOXP3, AIRE	• CTLA4 mutations (1.7–20.8%) and LRBA deficiency (0.9–7.2%) are major causes of immune dysregulation (tessarin2023monogenicformsof pages 4-5). • Over 50% of patients have inflammatory/autoimmune complications (alhakim2024thescopeand pages 2-4).
PI3K/AKT/mTOR Signaling	B cells, T cells	PI3Kδ hyperactivation (APDS); AKT/mTOR signaling	PIK3CD, PIK3R1, PTEN, TTC7A	• PIK3CD GOF causes APDS with lymphoproliferation and exhausted T cells (peng2023commonvariableimmunodeficiency pages 9-10, tessarin2023monogenicformsof pages 1-2). • Direct PI3K inhibitors approved for APDS (tessarin2023monogenicformsof pages 1-2, tessarin2023monogenicformsof pages 4-5).
T-cell Dysfunction & Help	CD4+ T cells, Tfh cells	T-cell activation; Cytokine production; Cytoskeletal dynamics	ICOS, MAGT1, PLCG2, RAC2, DOCK8	• T-cell defects documented in ~1/3 of CVID cases (alhakim2024thescopeand pages 2-4). • MAGT1 defects link magnesium transport to T-cell activation and EBV control (peng2023commonvariableimmunodeficiency pages 22-23).
Diagnostic Yield & Genetics	Systemic	NGS (WES/Targeted Panels)	N/A	• Monogenic causes identified in 20–50% of cases (alhakim2024thescopeand pages 2-4, cunninghamrundles2024commonvariableimmunodeficiency pages 1-2). • Diagnostic yield of NGS in PIDs is ~42%, higher with family history (~58%) (chen2024diagnosticyieldof pages 1-3).

Table: Summary of core pathophysiological mechanisms in Common Variable Immunodeficiency, including affected cells, pathways, representative genes, and key statistical evidence from recent literature.

Key references (with URLs and publication timing)

Peng XP, Caballero-Oteyza A, Grimbacher B. Common Variable Immunodeficiency: More Pathways than Roads to Rome. Annual Review of Pathology. Jan 2023. https://doi.org/10.1146/annurev-pathmechdis-031521-024229 (peng2023commonvariableimmunodeficiency pages 12-13)
Sircana MC et al. Common Variable Immunodeficiency and Selective IgA Deficiency: Focus on Autoimmune Manifestations and Their Pathogenesis. Int J Transl Med. Oct 2023. https://doi.org/10.3390/ijtm3040031 (sircana2023commonvariableimmunodeficiency pages 3-4)
Tessarin G et al. Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches. Curr Opin Allergy Clin Immunol. Sep 2023. https://doi.org/10.1097/aci.0000000000000947 (tessarin2023monogenicformsof pages 1-2)
Al‑Hakim A et al. The Scope and Impact of Viral Infections in CVID and CVID-like Disorders: A Literature Review. J Clin Med. Mar 2024. https://doi.org/10.3390/jcm13061717 (alhakim2024thescopeand pages 2-4)
Chen Y et al. Diagnostic yield of next-generation sequencing in suspect primary immunodeficiencies diseases: a systematic review and meta-analysis. Clin Exp Med. Jun 2024. https://doi.org/10.1007/s10238-024-01392-2 (chen2024diagnosticyieldof pages 1-3)
Cunningham‑Rundles C et al. Common variable immunodeficiency: autoimmune cytopenias and advances in molecular diagnosis. Hematology (ASH Education). Dec 2024. https://doi.org/10.1182/hematology.2024000538 (cunninghamrundles2024commonvariableimmunodeficiency pages 1-2)
Marsden JWN et al. Paucity of gastrointestinal plasma cells in common variable immunodeficiency. Curr Opin Allergy Clin Immunol. Oct 2024. https://doi.org/10.1097/aci.0000000000001040 (marsden2024paucityofgastrointestinal pages 1-2)

Notes on limitations of this synthesis

This report is constrained to mechanisms and quantitative statistics present in the retrieved full-text excerpts; some CVID-specific sequencing yield estimates and mechanistic details for particular pathways may require additional primary studies not yet retrieved in this run.
Some evidence items above (e.g., abatacept response rates) are derived from authoritative reviews summarizing multiple cohorts; interpretation should consider underlying study heterogeneity (tessarin2023monogenicformsof pages 4-5).

References

(alhakim2024thescopeand pages 2-4): Adam Al-Hakim, Mark Kacar, and Sinisa Savic. The scope and impact of viral infections in common variable immunodeficiency (cvid) and cvid-like disorders: a literature review. Journal of Clinical Medicine, 13:1717, Mar 2024. URL: https://doi.org/10.3390/jcm13061717, doi:10.3390/jcm13061717. This article has 8 citations.
(sircana2023commonvariableimmunodeficiency pages 3-4): Marta Chiara Sircana, Gianpaolo Vidili, Antonio Gidaro, Alessandro Palmerio Delitala, Fabiana Filigheddu, Roberto Castelli, and Roberto Manetti. Common variable immunodeficiency and selective iga deficiency: focus on autoimmune manifestations and their pathogenesis. International Journal of Translational Medicine, 3:432-460, Oct 2023. URL: https://doi.org/10.3390/ijtm3040031, doi:10.3390/ijtm3040031. This article has 7 citations.
(barbati2024monogeniccommonvariable pages 1-5): Federica Barbati, Lorenzo Lodi, Silvia Boscia, Martina Cortimiglia, Elisa Calistri, Francesca Quaranta, Laura Maggi, Alessio Mazzoni, Boaz Palterer, Francesco Annunziato, Chiara Azzari, and Silvia Ricci. Monogenic common variable immunodeficiency (mo-cvid) score for optimizing the diagnostic metamorphosis in pediatric cvid cohort. Unknown journal, Jun 2024. URL: https://doi.org/10.21203/rs.3.rs-4438029/v1, doi:10.21203/rs.3.rs-4438029/v1.
(cunninghamrundles2024commonvariableimmunodeficiency pages 1-2): Charlotte Cunningham-Rundles, Jean-Laurent Casanova, and Bertrand Boisson. Common variable immunodeficiency: autoimmune cytopenias and advances in molecular diagnosis. Hematology, 2024:137-142, Dec 2024. URL: https://doi.org/10.1182/hematology.2024000538, doi:10.1182/hematology.2024000538. This article has 10 citations and is from a peer-reviewed journal.
(peng2023commonvariableimmunodeficiency pages 7-9): Xiao P. Peng, Andrés Caballero-Oteyza, and Bodo Grimbacher. Common variable immunodeficiency: more pathways than roads to rome. Jan 2023. URL: https://doi.org/10.1146/annurev-pathmechdis-031521-024229, doi:10.1146/annurev-pathmechdis-031521-024229. This article has 65 citations and is from a domain leading peer-reviewed journal.
(peng2023commonvariableimmunodeficiency pages 9-10): Xiao P. Peng, Andrés Caballero-Oteyza, and Bodo Grimbacher. Common variable immunodeficiency: more pathways than roads to rome. Jan 2023. URL: https://doi.org/10.1146/annurev-pathmechdis-031521-024229, doi:10.1146/annurev-pathmechdis-031521-024229. This article has 65 citations and is from a domain leading peer-reviewed journal.
(peng2023commonvariableimmunodeficiency pages 22-23): Xiao P. Peng, Andrés Caballero-Oteyza, and Bodo Grimbacher. Common variable immunodeficiency: more pathways than roads to rome. Jan 2023. URL: https://doi.org/10.1146/annurev-pathmechdis-031521-024229, doi:10.1146/annurev-pathmechdis-031521-024229. This article has 65 citations and is from a domain leading peer-reviewed journal.
(peng2023commonvariableimmunodeficiency pages 12-13): Xiao P. Peng, Andrés Caballero-Oteyza, and Bodo Grimbacher. Common variable immunodeficiency: more pathways than roads to rome. Jan 2023. URL: https://doi.org/10.1146/annurev-pathmechdis-031521-024229, doi:10.1146/annurev-pathmechdis-031521-024229. This article has 65 citations and is from a domain leading peer-reviewed journal.
(peng2023commonvariableimmunodeficiency pages 13-15): Xiao P. Peng, Andrés Caballero-Oteyza, and Bodo Grimbacher. Common variable immunodeficiency: more pathways than roads to rome. Jan 2023. URL: https://doi.org/10.1146/annurev-pathmechdis-031521-024229, doi:10.1146/annurev-pathmechdis-031521-024229. This article has 65 citations and is from a domain leading peer-reviewed journal.
(tessarin2023monogenicformsof pages 4-5): Giulio Tessarin, Manuela Baronio, and Vassilios Lougaris. Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches. Current Opinion in Allergy and Clinical Immunology, 23:461-466, Sep 2023. URL: https://doi.org/10.1097/aci.0000000000000947, doi:10.1097/aci.0000000000000947. This article has 7 citations and is from a peer-reviewed journal.
(sircana2023commonvariableimmunodeficiency pages 4-6): Marta Chiara Sircana, Gianpaolo Vidili, Antonio Gidaro, Alessandro Palmerio Delitala, Fabiana Filigheddu, Roberto Castelli, and Roberto Manetti. Common variable immunodeficiency and selective iga deficiency: focus on autoimmune manifestations and their pathogenesis. International Journal of Translational Medicine, 3:432-460, Oct 2023. URL: https://doi.org/10.3390/ijtm3040031, doi:10.3390/ijtm3040031. This article has 7 citations.
(tessarin2023monogenicformsof pages 1-2): Giulio Tessarin, Manuela Baronio, and Vassilios Lougaris. Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches. Current Opinion in Allergy and Clinical Immunology, 23:461-466, Sep 2023. URL: https://doi.org/10.1097/aci.0000000000000947, doi:10.1097/aci.0000000000000947. This article has 7 citations and is from a peer-reviewed journal.
(marsden2024paucityofgastrointestinal pages 1-2): Jan Willem N. Marsden, Miangela M. Laclé, Mirjam Severs, and Helen Louisa Leavis. Paucity of gastrointestinal plasma cells in common variable immunodeficiency. Oct 2024. URL: https://doi.org/10.1097/aci.0000000000001040, doi:10.1097/aci.0000000000001040. This article has 8 citations and is from a peer-reviewed journal.
(chen2024diagnosticyieldof pages 1-3): Yingying Chen, Dongrui Li, Jiawen Yin, Jinglin Xiong, Min Xu, Qing Qi, and Wenlin Yang. Diagnostic yield of next-generation sequencing in suspect primary immunodeficiencies diseases: a systematic review and meta-analysis. Clinical and Experimental Medicine, Jun 2024. URL: https://doi.org/10.1007/s10238-024-01392-2, doi:10.1007/s10238-024-01392-2. This article has 8 citations and is from a peer-reviewed journal.
(marsden2024paucityofgastrointestinal pages 5-7): Jan Willem N. Marsden, Miangela M. Laclé, Mirjam Severs, and Helen Louisa Leavis. Paucity of gastrointestinal plasma cells in common variable immunodeficiency. Oct 2024. URL: https://doi.org/10.1097/aci.0000000000001040, doi:10.1097/aci.0000000000001040. This article has 8 citations and is from a peer-reviewed journal.
(marsden2024paucityofgastrointestinal pages 3-5): Jan Willem N. Marsden, Miangela M. Laclé, Mirjam Severs, and Helen Louisa Leavis. Paucity of gastrointestinal plasma cells in common variable immunodeficiency. Oct 2024. URL: https://doi.org/10.1097/aci.0000000000001040, doi:10.1097/aci.0000000000001040. This article has 8 citations and is from a peer-reviewed journal.
(marsden2024paucityofgastrointestinal pages 2-3): Jan Willem N. Marsden, Miangela M. Laclé, Mirjam Severs, and Helen Louisa Leavis. Paucity of gastrointestinal plasma cells in common variable immunodeficiency. Oct 2024. URL: https://doi.org/10.1097/aci.0000000000001040, doi:10.1097/aci.0000000000001040. This article has 8 citations and is from a peer-reviewed journal.

Ask OpenScientist

OpenScientist Report

Pathophysiology

Phenotypes

Genetic Associations

Treatments

Source YAML

References & Deep Research

Deep Research

Disease Pathophysiology Research Template

Target Disease

Research Objectives

Required Information

1. Core Pathophysiology

2. Key Molecular Players

3. Biological Processes (for GO annotation)

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

Citation Requirements

Output Format

Comprehensive Research Report: Common Variable Immunodeficiency (CVID) Pathophysiology (Molecular/Cellular)

Disease identifiers and classification

1. Key concepts and definitions (current understanding)

Definition (clinical-immunologic)

Epidemiology and baseline quantitative features

“CVID+” immune dysregulation endotype

2. Core pathophysiology (molecular and cellular mechanisms)

2.1 B-cell developmental/GC output failure (central axis)

2.2 BAFF/APRIL–TACI axis and NF-κB signaling (B-cell survival and plasma cell differentiation)

2.3 PI3Kδ–AKT–mTOR pathway dysregulation (APDS and GC disruption)

2.4 T-cell help and tolerance checkpoints (Tfh/Treg/CTLA-4–LRBA)

2.5 Additional mechanistic routes (DNA repair, transcriptional regulation, organelle/trafficking)

3. Key molecular players (genes/proteins, cells, tissues, chemicals)

3.1 Genes/Proteins (HGNC symbols)

3.2 Chemical entities / therapeutics (CHEBI-relevant entities)

3.3 Cell types (Cell Ontology; CL terms suggested)

3.4 Anatomical locations (UBERON suggested)

4. Biological processes and pathways (GO-oriented annotation candidates)

5. Cellular components (GO-CC candidates)

6. Disease progression: mechanistic sequence (model)

7. Phenotypic manifestations and mechanism links (HP-oriented)

8. Recent developments (prioritizing 2023–2024)

8.1 Genetics: increasing recognition of monogenic drivers and stratification tools

8.2 Diagnostic yield of sequencing in PID (generalizable implementation evidence)

8.3 Targeted therapies: pathway-directed treatment for CVID-like immune dysregulation

8.4 GI pathophysiology: standardizing plasma-cell paucity metrics in CVID enteropathy

9. Current applications and real-world implementations

9.1 Standard of care

9.2 Precision medicine in monogenic CVID-like disease

9.3 Diagnostic implementation: integrating immunophenotype + genomics

10. Expert opinions / authoritative synthesis (review-derived analysis)

Structured knowledge-base elements

Pathophysiology description (knowledge-base ready)

Gene/protein annotations (HGNC; representative set)

GO biological process candidates (selected)

Cell types (CL candidates)

Anatomical locations (UBERON candidates)

Chemical entities (selected)

Evidence tables

Key references (with URLs and publication timing)

Notes on limitations of this synthesis